1,033 results on '"Forconi, Francesco"'
Search Results
2. XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression
3. Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL
4. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial
5. The essential microenvironmental role of oligomannoses specifically inserted into the antigen-binding sites of lymphoma cells
6. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
7. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
8. Mutations in the IgG B cell receptor associated with class-switched B cell lymphomas
9. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
10. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
11. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment
12. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells
13. Proliferative History Is a Novel Driver of Clinical Outcome in Splenic Marginal Zone Lymphoma
14. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
15. The essential microenvironmental role of oligomannoses inserted into the antigen-binding sites of lymphoma cells
16. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
17. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL
18. DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity
19. Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia
20. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
21. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
22. PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
23. S142: FOXO1-RICTOR AXIS INDUCES ADAPTIVE INCREASE IN AKT ACTIVITY DURING BCR INHIBITOR THERAPY IN CLL: IMPLICATIONS FOR COMBINATION THERAPY
24. PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
25. Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter’s syndrome: therapeutic implications
26. BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia
27. BCL2 Inhibition in Refractory Hairy-Cell Leukemia
28. Hairy cell leukemia variant and WHO classification correspondence Re: 5thedition WHO classification haematolymphoid tumors: lymphoid neoplasms
29. Supplementary methods and Figures from The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
30. Supplementary Figure 1 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
31. Supplementary Table 4 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
32. Supplementary Figure 2 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
33. Supplementary Tables 1-3 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
34. Supplementary Table 6 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
35. Supplementary Table 5 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
36. Supplementary Tables S1-S4 from The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
37. Supplementary Data from Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome
38. Data from STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy
39. Supplementary Data from Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells
40. Supplementary Table 7 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
41. CCR Translation for this Article from Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features
42. Supplemetary data from STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy
43. Supplementary Data from Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features
44. Supplementary Tables and Figures from Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients
45. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
46. Development of DNA vaccines against B-cell neoplasms
47. Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL
48. MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study
49. Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study
50. DC-SIGN Binding to the Oligomannose-Type Glycans on the Surface Immunoglobulin Variable Region of Follicular Lymphoma Promotes Selective Adhesion to Microenvironmental VCAM-1
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.